05:18:48 EDT Fri 17 May 2024
Enter Symbol
or Name
USA
CA



EvokAI Creative Labs Inc
Symbol OKAI
Shares Issued 72,507,609
Close 2023-06-23 C$ 2.11
Market Cap C$ 152,991,055
Recent Sedar Documents

EvokAI Creative completes Rehaboo acquisition

2023-06-26 15:05 ET - News Release

Mr. Alejandro Antalich reports

EVOKAI CREATIVE LABS ACQUIRES AI-POWERED COMPANY REHABOO OY

EvokAI Creative Labs Inc. has completed the acquisition of Rehaboo Oy. Rehaboo's main product is a versatile physical gamification platform based on high-definition motion-sensing technology, powered by artificial intelligence ("AI") to promote an active lifestyle and brain health in any environment. The Acquisition was previously announced on May 11, 2023.

"With the acquisition of Rehaboo, a trailblazing company at the forefront of leveraging gamification to fight inactivity, we continue to strengthen our mission to revolutionize the healthcare industry and empower individuals to adopt healthier lifestyles. By combining resources, knowledge, and expertise, we are expanding our reach in the medtech industry, accelerating the development and deployment of our gamification platform on a global scale, enabling millions of individuals to take control of their brain and body health, regardless the income level due to the unique approach that transforms the human body into a game controller," said Alejandro Antalich, CEO and Director of EvokAI Creative Labs.

As part of the acquisition, EvokAI has retained key talent from Rehaboo to ensure a seamless transition and continuity of operations. The integration of Rehaboo's technology and know-how within EvokAI's ecosystem will open up new avenues for innovation and disruption in the gamification era, further driving advancements in the early detection of neurological disorders.

Rehaboo's Active cloud-based AI gaming platform is a solution that analyzes, learns, improves, and predicts from players' movement and cognitive activation. It is currently being used at hospitals, elderly care homes, and as a home care solution in tens of locations in Finland and Denmark, also in research pilots in Singapore and Oslo, Norway. Rehaboo's platform has the potential to tackle the burden of several diseases associated with cognitive functions and inactivity. In addition, the platform provides vast improvement in home care through accessibility and by creating a sort of metaverse for elderly generation, where players can exercise while joining a playful competition with an avatar.

Created by renowned neuroscientists and physical therapy professionals, Rehaboo's platform improves blood flow to the brain and cognitive functions, whilst promoting the growth of new brain cells. Its uniqueness, easy to scale and novel algorithms provide data analytics, real-time feedback and progress tracking. Most relevant is the platform's ability to adapt according to users' capabilities. It analyzes movements and provides personalized feedback on form and technique, also adjusting the difficulty level based on the user's performance.

Pursuant to the terms of the Acquisition, the Company acquired 100% of the issued and outstanding securities of Rehaboo in consideration of the issuance of an aggregate of 3,547,321 common shares of the Company at a deemed value of $1.53 per common share ("EvokAI Shares") to former securityholders of Rehaboo. The EvokAI Shares issued in connection with the Acquisition are subject to a contractual hold period expiring November 30, 2023.

No finder's fees were paid or applicable in connection with the Acquisition.

About EvokAI Creative Labs Inc.

EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. We deploy machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.